Literature DB >> 33769740

Atenolol use for infantile hemangiomas.

Rosalia Ballona1, Felipe Velásquez'1, Iris Kikushima1, Jean Pierre Zevallos2, Jeanette Nuñez3, Consuelo Apagüeño1.   

Abstract

Entities:  

Year:  2021        PMID： 33769740     DOI： 10.25259/IJDVL_687_19

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  6 in total

1.  Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review.

Authors:  Qi Wang; Bo Xiang; Siyuan Chen; Yi Ji
Journal:  Australas J Dermatol       Date:  2018-12-04       Impact factor: 2.875

Review 2.  Clinical Practice Guideline for the Management of Infantile Hemangiomas.

Authors:  Daniel P Krowchuk; Ilona J Frieden; Anthony J Mancini; David H Darrow; Francine Blei; Arin K Greene; Aparna Annam; Cynthia N Baker; Peter C Frommelt; Amy Hodak; Brian M Pate; Janice L Pelletier; Deborah Sandrock; Stuart T Weinberg; Mary Anne Whelan
Journal:  Pediatrics       Date:  2019-01       Impact factor: 7.124

3.  Atenolol treatment for severe Infantile Hemangiomas: a single-centre prospective study.

Authors:  A Alexopoulos; I Thanopoulou; M Dakoutrou; E Georgiadou; G P Chrousos; T Kakourou
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-06       Impact factor: 6.166

4.  Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.

Authors:  Cheryl B Bayart; Joan E Tamburro; Allison T Vidimos; Lu Wang; Alex B Golden
Journal:  Pediatr Dermatol       Date:  2017-05-28       Impact factor: 1.588

5.  Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas.

Authors:  Megan E Gumina; Albert C Yan
Journal:  Pediatr Dermatol       Date:  2019-04-15       Impact factor: 1.588

6.  Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.

Authors:  Yi Ji; Siyuan Chen; Qi Wang; Bo Xiang; Zhicheng Xu; Lin Zhong; Kaiying Yang; Guoyan Lu; Liqin Qiu
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.